MorphoSys AG (ETR:MOR) has been assigned a €85.00 ($100.00) price objective by J P Morgan Chase & Co in a research note issued on Friday. The brokerage presently has a “buy” rating on the stock.

A number of other equities research analysts also recently weighed in on MOR. Independent Research GmbH set a €84.00 ($98.82) price objective on MorphoSys AG and gave the company a “buy” rating in a research report on Wednesday. Oddo Bhf set a €81.00 ($95.29) price objective on MorphoSys AG and gave the company a “buy” rating in a research report on Monday, September 25th. Commerzbank Ag set a €76.00 ($89.41) price objective on MorphoSys AG and gave the company a “buy” rating in a research report on Wednesday, September 27th. Goldman Sachs Group, Inc. (The) set a €72.00 ($84.71) price objective on MorphoSys AG and gave the company a “neutral” rating in a research report on Thursday, September 28th. Finally, Deutsche Bank AG set a €90.00 ($105.88) price objective on MorphoSys AG and gave the company a “buy” rating in a research report on Monday, August 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of €76.88 ($90.44).

MorphoSys AG (ETR MOR) opened at 74.217 on Friday. The stock has a 50 day moving average of €64.90 and a 200 day moving average of €60.84. The firm’s market capitalization is €2.15 billion. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €75.00.

TRADEMARK VIOLATION NOTICE: “MorphoSys AG (MOR) Given a €85.00 Price Target at J P Morgan Chase & Co” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/morphosys-ag-mor-given-a-85-00-price-target-at-j-p-morgan-chase-co/1611450.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.